Unknown

Dataset Information

0

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension.


ABSTRACT: We compared the haemodynamic effects of riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent/recurrent CTEPH after pulmonary endarterectomy in the Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase-Stimulator Trial 1 study.Patients with inoperable or persistent/recurrent CTEPH (n=261; mean± SD age 59±14?years; 66% women) were randomised to riociguat (up to 2.5?mg three times daily) or placebo. Haemodynamic parameters were assessed at baseline and week 16.Riociguat decreased pulmonary vascular resistance (PVR) in inoperable (n=189; least-squares mean difference: -285?dyn?s/cm5 (95% CI -357 to -213); p<0.0001) and persistent/recurrent (n=72; -131 dyn?s/cm5 (95% CI -214 to -48); p=0.0025) patients. Cardiac index improved in inoperable patients by a least-squares mean difference of +0.6?L/min/m2 (95% CI 0.4 to 0.7; p<0.0001), while in persistent/recurrent patients the change was +0.2?L/min/m2 (95% CI -0.1 to 0.5; p=0.17). Mean pulmonary artery pressure decreased in inoperable and persistent/recurrent patients(-4.7?mm?Hg (95% CI -6.9 to -2.6; p<0.0001 and -4.8?mm?Hg (-8.2 to -1.5; p=0.0055), respectively). For all patients, changes in 6?min walk distance correlated with changes in PVR (r=-0.29 (95% CI -0.41 to -0.17); p<0.0001) and cardiac index (r=0.23 (95% CI 0.10 to 0.35); p=0.0004).Riociguat improved haemodynamics in patients with inoperable CTEPH or persistent/recurrent CTEPH.NCT00855465.

SUBMITTER: Kim NH 

PROVIDER: S-EPMC5529957 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension.

Kim Nick H NH   D'Armini Andrea M AM   Grimminger Friedrich F   Grünig Ekkehard E   Hoeper Marius M MM   Jansa Pavel P   Mayer Eckhard E   Neurohr Claus C   Simonneau Gérald G   Torbicki Adam A   Wang Chen C   Fritsch Arno A   Davie Neil N   Ghofrani Hossein-Ardeschir HA  

Heart (British Cardiac Society) 20161223 8


<h4>Objective</h4>We compared the haemodynamic effects of riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent/recurrent CTEPH after pulmonary endarterectomy in the Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase-Stimulator Trial 1 study.<h4>Methods</h4>Patients with inoperable or persistent/recurrent CTEPH (n=261; mean± SD age 59±14 years; 66% women) were randomised to riociguat (up to 2.5 mg three times daily) or plac  ...[more]

Similar Datasets

| S-EPMC6671827 | biostudies-literature
| S-EPMC9491640 | biostudies-literature
| S-EPMC6540507 | biostudies-literature
| S-EPMC7046957 | biostudies-literature
| S-EPMC8711204 | biostudies-literature
| S-EPMC7959461 | biostudies-literature
| S-EPMC6396196 | biostudies-literature
| S-EPMC5745920 | biostudies-literature
| S-EPMC7489461 | biostudies-literature
| S-EPMC9685142 | biostudies-literature